A newly published study in the Journal of Expert Opinion on Biological Therapy highlights the recent developments in the setting of endometriosis management. In the latest investigations, it was found that some of the females experience partial or no reduction in pain or its recurrence after the discontinuation of treatments like combined hormonal contraceptives and progestins, which are currently present as the first-line treatments for endometriosis. This is why new medications or treatments are needed for endometriosis management.

The most promising results regarding endometriosis treatment were shown by the aromatase inhibitors (AIs) and gonadotropin-releasing hormone (GnRH) antagonists. One of the GnRH, Elagolix also got approval by the Food and Drug Administration (FDA) for operating endometriosis. Other medications were also recognized but the majority these have only been assessed in early clinical trials or pre-clinical studies. Additional extensive clinical research is needed to illustrate their efficacy, safety and pharmacological characteristics in a better way.